Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease‐defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification. This rating was mainly based on a retrospective analysis comprising patients from several large clinical trials, which, however, included only 21 patients treated with allogeneic stem cell transplantation (alloSCT). Therefore, the European Society for Blood and Marrow Transplantation performed a registry study on a larger cohort to evaluate the role of alloSCT in t(8;16) AML. Sixty transplant recipients with t(8;16) AML were identified. Two‐year overall and leukemia‐free survival (OS/LFS) was 43/39%. Patients transplanted in first complete remission (CR1, n = 44) achieved a 2‐year OS/LFS of 48%/48%. Following alloSCT in CR1, the multivariable analysis identified a complex karyotype (CK) as a major risk factor for relapse (HR 4.17, p = .016), lower LFS (HR 3.38, p = .01), and lower OS (HR 3.08, p = .017). Two‐year OS/LFS of patients with CK was 19%/19%, in contrast to 67%/67% in patients with t(8;16) outside a CK. Other factors for inferior outcomes were older age and secondary AML. In summary, alloSCT could mitigate the adverse risk of patients with t(8;16) AML not harboring a CK, particularly when performed in CR1.

中文翻译：

---

同种异体干细胞移植在易位 t（8;16）（第 11 页;第 13 页）


易位 t（8;16）（第 11 页;p13） 代表一种罕见的实体，在 2022 年欧洲白血病网分类中被归类为具有不良风险的疾病定义性复发性细胞遗传学异常。该评级主要基于一项回顾性分析，该分析包括来自几项大型临床试验的患者，但仅包括 21 名接受同种异体干细胞移植 （alloSCT） 治疗的患者。因此，欧洲血液和骨髓移植学会对更大的队列进行了一项登记研究，以评估 alloSCT 在 t（8;16） 反洗钱。60 例移植受者 t（8;16） 确定了 AML。两年总生存率和无白血病生存率 （OS/LFS） 为 43/39%。首次完全缓解移植的患者 （CR1，n = 44） 的 2 年 OS/LFS 为 48%/48%。在 CR1 中同种异体 SCT 后，多变量分析确定复杂核型 （CK） 是复发 （HR 4.17，p = .016）、较低 LFS （HR 3.38，p = .01） 和较低 OS （HR 3.08，p = .017） 的主要危险因素。CK 患者的两年 OS/LFS 为 19%/19%，而 t（8;16） 在 CK 之外。其他导致结局较差的因素是高龄和继发性 AML。总之，alloSCT 可以减轻 t（8;16） AML 不携带 CK，尤其是在 CR1 中进行时。